Cancer is the second most common cause of death in the US, exceeded only by heart disease. The financial costs of cancer treatment are a burden to people diagnosed with cancer, their families, and society as a whole. The National Institutes of Health (NIH) estimates overall costs of cancer care in 2010 at $263.8 billion. Currently used cancer drugs such as chemotherapeutic agents and monoclonal antibodies have limitations due to their toxicities and are ineffective against tumors with drug resistance. Thus, there is an urgent need for more potent, targeted and safer cancer therapeutics.
Oncotherapy Solutions, a new biotechnology company is utilizing its previous expertise in preclinical drug development to design and test new pipeline of targeted, potent, stable and safer drugs for the treatment of colon, prostate, breast, pancreatic, lung and other cancers. The company currently has two active preclinical programs. The first is the development of novel peptide analogs with pro-apoptotic, pro-necrotic and anti-proliferative activities on human cancers. The second program is the development of novel, efficient, specific and safer delivery systems for siRNA/microRNA, chemotherapeutic agents as well as peptides with anti-proliferative and pro-apoptotic activities to cancer cells.